Expanding Precision Particle Fabrication Technology for the Widespread Control of
Expanding Precision Particle Fabrication Technology for the Widespread Control of
批准号:
8089561
负责人:
Cory Berkland
金额:
$34.57万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-06-15 至 2012-10-28
关键词:
AnalgesicsAntibioticsBedsBeveragesBiologicalBiological AvailabilityBusinessesCharacteristicsChemicalsChildhoodDevelopmentDiseaseDoseDrug ControlsDrug Delivery SystemsDrug IndustryEffectivenessEncapsulatedEquipmentFailureFiltrationFundingFutureGastrointestinal tract structureGelGoalsGrantGuidelinesHealthHumanIndustryLaboratoriesLiquid substanceManufacturer NameMarketingMasksMechanicsMethodsMicrocapsules drug delivery systemMicroencapsulationsMonitorMorphologyNutrientOilsParticle SizePatientsPerformancePharmaceutical PreparationsPharmacologic SubstancePhasePositioning AttributePractice GuidelinesProcessProductionPropertyRecyclingResearchResearch PersonnelSolubilitySolutionsSolventsStreamSuctionSystemTaste PerceptionTechnologyTestingTranslatingValidationVitamin EWaterbasecontrolled releasecostdesigndrug developmentexperienceflexibilityimprovedin vivoindustry partnerinnovationmeetingsnovelnovel therapeuticsparticlephysical propertyproduct developmentprototypepublic health relevanceresearch and developmentscale upwasting
中文摘要
描述(由申请人提供):该项目的总体目标是开发一种可扩展的工艺,用于制造具有均匀尺寸和物理特性的油封装颗粒,其中含有油作为输送疏水药物的载体。低水溶性活性药物成分(api)占制药工业发现的所有新化学实体的40%,但研究人员经常在研发阶段放弃它们,因为它们的不溶性使它们难以配制,这转化为低和/或可变的生物利用度和体内有效性。溶解度问题也降低了市场上很大一部分产品的功效,包括许多止痛药和抗生素。我们新颖的精密颗粒制造(PPF)技术是一种灵活的单步工艺,用于制造具有精细调节尺寸和物理化学特性的含油颗粒,从而改善对药物封装和释放的控制。我们假设,该技术的缩放版本将以至少10公斤/分钟的速度生产干燥的,充满油的微胶囊(尺寸<100米),足以满足工业需求。第一阶段的研究将证明PPF技术在制药公司广泛应用的可行性。我们的研究团队将开发现有PPF技术的几个缩放原型,以满足一系列不同的微胶囊规格(目标1)。我们还将该技术与FDA给出的现行良好生产规范指南(目标2)相结合,并为该工艺设计监测机制和流体回收,以减少材料浪费(目标3)。PPF给药技术的成功规模化将改善现有药品的生物性能,并使使用以前在药物开发过程中丢弃的原料药生产新的治疗溶液成为可能。
英文摘要
DESCRIPTION (provided by applicant): This overall goal of this project is to develop a scalable process for fabricating oil encapsulated particles with uniform sizes and physical characteristics that contain oil as a vehicle for delivering hydrophobic drugs. Poorly water soluble active pharmaceutical ingredients (APIs) represent 40% of all new chemical entities discovered by the pharmaceutical industry, but investigators often discard them in the R&D phase because their insolubility renders them difficult to formulate, which translates to low and/or variable bioavailability and effectiveness in vivo. Solubility problems also decrease the efficacy of a significant portion of products on the market, including many pain relievers and antibiotics. Our novel Precision Particle Fabrication (PPF) technology is a flexible, single-step process for fabricating oil-containing particles with finely tuned sizes and physicochemical characteristics that enable improved control over drug encapsulation and release. We hypothesize that a scaled version of this technology will produce dried, oil-filled microcapsules (size <100 5m) at a rate of at least 10 kg/min, more than adequate for industry needs. Phase I research will demonstrate the feasibility of scaling PPF technology for broad use by pharmaceutical companies. Our research team will develop several scaled prototypes of the existing PPF technology to meet a range of varying microcapsule specifications (Aim 1). We will also integrate the technology with current Good Manufacturing Practice guidelines given by the FDA (Aim 2) and design a monitoring mechanism and fluid recycling for the process to decrease material waste (Aim 3). Successful scaling of the PPF technology for drug delivery will improve the biological performance of existing pharmaceutical products and enable production of new therapeutic solutions using APIs previously discarded in the drug development process.
PUBLIC HEALTH RELEVANCE: Development of effective delivery mechanisms for pharmaceutical products is just as important as the drugs themselves for treatment of disease. However, pharmaceutical companies have yet to discover a reliable, scalable process for consistently fabricating drug particles with controlled physical properties and release profiles. This project aims to test the feasibility of expanding a novel method for fabricating particles with well-defined and tunable properties from the laboratory setting to the broader marketplace by leveraging encapsulated oil as a delivery vehicle for poorly- soluble drugs.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Preparing BBI-001 as an oral, non-absorbed iron chelator for prevention of iron overload
-
批准号:10258539
-
项目类别:
-
资助金额:$29.94万
-
财政年份:2021
-
负责人:Cory Berkland
-
依托单位:
Engineering Microparticles for Taste-Masking and Controlled Release of Pediatric
-
批准号:8396082
-
项目类别:
-
资助金额:$21.6万
-
财政年份:2012
-
负责人:Cory Berkland
-
依托单位:
Precision Particle Fabrication-enabled Betamethasone-loaded Microspheres for Tran
-
批准号:8396087
-
项目类别:
-
资助金额:$28.71万
-
财政年份:2012
-
负责人:Cory Berkland
-
依托单位:
Integrative colloidal gels for cranial defect repair
-
批准号:8433328
-
项目类别:
-
资助金额:$35.71万
-
财政年份:2012
-
负责人:Cory Berkland
-
依托单位:
Integrative colloidal gels for cranial defect repair
-
批准号:8239401
-
项目类别:
-
资助金额:$35.92万
-
财政年份:2012
-
负责人:Cory Berkland
-
依托单位:
Targeted nanoscale antigen arrays for treating autoimmune diseases
-
批准号:8513574
-
项目类别:
-
资助金额:$38.13万
-
财政年份:2012
-
负责人:Cory Berkland
-
依托单位:
Integrative colloidal gels for cranial defect repair
-
批准号:8804184
-
项目类别:
-
资助金额:$29.67万
-
财政年份:2012
-
负责人:Cory Berkland
-
依托单位:
Integrative colloidal gels for cranial defect repair
-
批准号:8607930
-
项目类别:
-
资助金额:$35.96万
-
财政年份:2012
-
负责人:Cory Berkland
-
依托单位:
Multi-day Pain Management Therapy with Novel Injectable Formulation
-
批准号:8198342
-
项目类别:
-
资助金额:$25.37万
-
财政年份:2011
-
负责人:Cory Berkland
-
依托单位:
Expanding Precision Particle Fabrication Technology for the Widespread Control of
-
批准号:7908631
-
项目类别:
-
资助金额:$34.95万
-
财政年份:2010
-
负责人:Cory Berkland
-
依托单位:
BIODEGRADABLE NANOPARTICLES FOR AIDS GENE THERAPY
-
批准号:7959699
-
项目类别:
-
资助金额:$26.71万
-
财政年份:2009
-
负责人:Cory Berkland
-
依托单位:
BIODEGRADABLE NANOPARTICLES FOR AIDS GENE THERAPY
-
批准号:7720554
-
项目类别:
-
资助金额:$24.61万
-
财政年份:2008
-
负责人:Cory Berkland
-
依托单位:
TRACEABLE CANCER-TARGETED NANOPARTICLES FOR LOCALIZED CHEMOTHERAPY
-
批准号:7609711
-
项目类别:
-
资助金额:$3.35万
-
财政年份:2007
-
负责人:Cory Berkland
-
依托单位:
Nanoparticle targeting of ICAM-1 as a potential treatment for Rheumatoid Arthriti
-
批准号:7660520
-
项目类别:
-
资助金额:$6.83万
-
财政年份:2007
-
负责人:Cory Berkland
-
依托单位:
Nanoparticle targeting of ICAM-1 as a potential treatment for Rheumatoid Arthriti
-
批准号:7488597
-
项目类别:
-
资助金额:$6.8万
-
财政年份:2007
-
负责人:Cory Berkland
-
依托单位:
BIODEGRADABLE NANOPARTICLES FOR AIDS GENE THERAPY
-
批准号:7609904
-
项目类别:
-
资助金额:$25.24万
-
财政年份:2007
-
负责人:Cory Berkland
-
依托单位:
Nanoparticle targeting of ICAM-1 as a potential treatment for Rheumatoid Arthriti
-
批准号:7304759
-
项目类别:
-
资助金额:$6.91万
-
财政年份:2007
-
负责人:Cory Berkland
-
依托单位:
TRACEABLE CANCER-TARGETED NANOPARTICLES FOR LOCALIZED CHEMOTHERAPY
-
批准号:7381090
-
项目类别:
-
资助金额:$6.15万
-
财政年份:2006
-
负责人:Cory Berkland
-
依托单位:
TRACEABLE CANCER-TARGETED NANOPARTICLES FOR LOCALIZED CHEMOTHERAPY
-
批准号:7170249
-
项目类别:
-
资助金额:$1.48万
-
财政年份:2005
-
负责人:Cory Berkland
-
依托单位:
海外基金